Exercise training as a novel primary treatment for localised prostate cancer: a multi-site randomised controlled phase II study

Abstract Alternative management strategies for localised prostate cancer are required to reduce morbidity and overtreatment. The aim of this study was to evaluate the feasibility, safety and acceptability of exercise training (ET) with behavioural support as a primary therapy for low/intermediate ri...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	L. Bourke, R. Stevenson, R. Turner, R. Hooper, P. Sasieni, R. Greasley, D. Morrissey, M. Loosemore, A. Fisher, H. Payne, S. J. C. Taylor, D. J. Rosario
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/6666e6d5b1ad46edab36cfa782d26abf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6666e6d5b1ad46edab36cfa782d26abf
record_format	dspace
spelling	oai:doaj.org-article:6666e6d5b1ad46edab36cfa782d26abf2021-12-02T15:08:56ZExercise training as a novel primary treatment for localised prostate cancer: a multi-site randomised controlled phase II study10.1038/s41598-018-26682-02045-2322https://doaj.org/article/6666e6d5b1ad46edab36cfa782d26abf2018-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-018-26682-0https://doaj.org/toc/2045-2322Abstract Alternative management strategies for localised prostate cancer are required to reduce morbidity and overtreatment. The aim of this study was to evaluate the feasibility, safety and acceptability of exercise training (ET) with behavioural support as a primary therapy for low/intermediate risk localised prostate cancer. Men with low/intermediate-risk prostate cancer were randomised to 12 months of ET or usual care with physical activity advice (UCwA) in a multi-site open label RCT. Feasibility included acceptability, recruitment, retention, adherence, adverse events and disease progression. Secondary outcomes included quality of life and cardiovascular health indices. Of the 50 men randomised to ET (n = 25) or UCwA (n = 25), 92% (n = 46) completed 12 month assessments. Three men progressed to invasive therapy (two in UCwA). In the ET group, men completed mean: 140 mins per week for 12 months (95% CI 129,152 mins) (94% of target dose) at 75% Hrmax. Men in the ET group demonstrated improved body mass (mean reduction: 2.0 kg; 95% CI −2.9,−1.1), reduced systolic (mean: 13 mmHg; 95%CI 7,19) and diastolic blood pressure (mean:8 mmHg; 95% CI 5,12) and improved quality of life (EQ.5D mean:13 points; 95% CI 7,18). There were no serious adverse events. ET in men with low/intermediate risk prostate cancer is feasible and acceptable with a low progression rate to radical treatment. Early signals on clinically relevant markers were found which warrant further investigation.L. BourkeR. StevensonR. TurnerR. HooperP. SasieniR. GreasleyD. MorrisseyM. LoosemoreA. FisherH. PayneS. J. C. TaylorD. J. RosarioNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 8, Iss 1, Pp 1-10 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q L. Bourke R. Stevenson R. Turner R. Hooper P. Sasieni R. Greasley D. Morrissey M. Loosemore A. Fisher H. Payne S. J. C. Taylor D. J. Rosario Exercise training as a novel primary treatment for localised prostate cancer: a multi-site randomised controlled phase II study
description	Abstract Alternative management strategies for localised prostate cancer are required to reduce morbidity and overtreatment. The aim of this study was to evaluate the feasibility, safety and acceptability of exercise training (ET) with behavioural support as a primary therapy for low/intermediate risk localised prostate cancer. Men with low/intermediate-risk prostate cancer were randomised to 12 months of ET or usual care with physical activity advice (UCwA) in a multi-site open label RCT. Feasibility included acceptability, recruitment, retention, adherence, adverse events and disease progression. Secondary outcomes included quality of life and cardiovascular health indices. Of the 50 men randomised to ET (n = 25) or UCwA (n = 25), 92% (n = 46) completed 12 month assessments. Three men progressed to invasive therapy (two in UCwA). In the ET group, men completed mean: 140 mins per week for 12 months (95% CI 129,152 mins) (94% of target dose) at 75% Hrmax. Men in the ET group demonstrated improved body mass (mean reduction: 2.0 kg; 95% CI −2.9,−1.1), reduced systolic (mean: 13 mmHg; 95%CI 7,19) and diastolic blood pressure (mean:8 mmHg; 95% CI 5,12) and improved quality of life (EQ.5D mean:13 points; 95% CI 7,18). There were no serious adverse events. ET in men with low/intermediate risk prostate cancer is feasible and acceptable with a low progression rate to radical treatment. Early signals on clinically relevant markers were found which warrant further investigation.
format	article
author	L. Bourke R. Stevenson R. Turner R. Hooper P. Sasieni R. Greasley D. Morrissey M. Loosemore A. Fisher H. Payne S. J. C. Taylor D. J. Rosario
author_facet	L. Bourke R. Stevenson R. Turner R. Hooper P. Sasieni R. Greasley D. Morrissey M. Loosemore A. Fisher H. Payne S. J. C. Taylor D. J. Rosario
author_sort	L. Bourke
title	Exercise training as a novel primary treatment for localised prostate cancer: a multi-site randomised controlled phase II study
title_short	Exercise training as a novel primary treatment for localised prostate cancer: a multi-site randomised controlled phase II study
title_full	Exercise training as a novel primary treatment for localised prostate cancer: a multi-site randomised controlled phase II study
title_fullStr	Exercise training as a novel primary treatment for localised prostate cancer: a multi-site randomised controlled phase II study
title_full_unstemmed	Exercise training as a novel primary treatment for localised prostate cancer: a multi-site randomised controlled phase II study
title_sort	exercise training as a novel primary treatment for localised prostate cancer: a multi-site randomised controlled phase ii study
publisher	Nature Portfolio
publishDate	2018
url	https://doaj.org/article/6666e6d5b1ad46edab36cfa782d26abf
work_keys_str_mv	AT lbourke exercisetrainingasanovelprimarytreatmentforlocalisedprostatecanceramultisiterandomisedcontrolledphaseiistudy AT rstevenson exercisetrainingasanovelprimarytreatmentforlocalisedprostatecanceramultisiterandomisedcontrolledphaseiistudy AT rturner exercisetrainingasanovelprimarytreatmentforlocalisedprostatecanceramultisiterandomisedcontrolledphaseiistudy AT rhooper exercisetrainingasanovelprimarytreatmentforlocalisedprostatecanceramultisiterandomisedcontrolledphaseiistudy AT psasieni exercisetrainingasanovelprimarytreatmentforlocalisedprostatecanceramultisiterandomisedcontrolledphaseiistudy AT rgreasley exercisetrainingasanovelprimarytreatmentforlocalisedprostatecanceramultisiterandomisedcontrolledphaseiistudy AT dmorrissey exercisetrainingasanovelprimarytreatmentforlocalisedprostatecanceramultisiterandomisedcontrolledphaseiistudy AT mloosemore exercisetrainingasanovelprimarytreatmentforlocalisedprostatecanceramultisiterandomisedcontrolledphaseiistudy AT afisher exercisetrainingasanovelprimarytreatmentforlocalisedprostatecanceramultisiterandomisedcontrolledphaseiistudy AT hpayne exercisetrainingasanovelprimarytreatmentforlocalisedprostatecanceramultisiterandomisedcontrolledphaseiistudy AT sjctaylor exercisetrainingasanovelprimarytreatmentforlocalisedprostatecanceramultisiterandomisedcontrolledphaseiistudy AT djrosario exercisetrainingasanovelprimarytreatmentforlocalisedprostatecanceramultisiterandomisedcontrolledphaseiistudy
_version_	1718387942690390016

Exercise training as a novel primary treatment for localised prostate cancer: a multi-site randomised controlled phase II study

Ejemplares similares